Renal transplant, cardiovascular disease
Conditions
Interventions
Prospective, randomized, controlled study including patients with recent kidney transplant and regularly followed in outpatient post-transplant in the Oswaldo Ramos, UNIFESP. Were selected and randomi
Drug
Sponsors
Universidade Federal de São Paulo
Universidade Federal de São Paulo
Eligibility
Inclusion criteria
Inclusion criteria: Kidney Transplant for within two months
Exclusion criteria
Exclusion criteria: Age below 18 years or above 60 years, creatinine clearance lower than 30 ml/min, patients prioritized for kidney transplantation and patients who had experienced any cardiovascular events 3 months prior to transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In the evaluation of cardiovascular disease after 12 months of intervention, there was no regression of coronary calcification using rosuvastatin, observed by calcium score obtained with CT. A statistical model of generalized estimating equations, which did not find a significance level of 0.05 (; time effect p = 0.70; interaction p = 0.92 group effect p = 0.06) was obtained. There was no difference between echocardiographic parameters or pulse wave velocity analyzed. | — |
Secondary
| Measure | Time frame |
|---|---|
| There were no differences in cardiovascular mortality or occurrence of cardiovascular disease after 12 months using rosuvastatin. However, in the univariate analysis there was a statistical difference in improvement in renal function, calculated from the MDRD (p <0.001) and stabilization of inflammation, dosed by examining the PCR (p = 0.01) in those patients who used statins in the control group. | — |
Countries
Brazil
Contacts
Public ContactDANIEL YAZBEK
Universidade Federal de São Paulo
Outcome results
None listed